Published in J Clin Endocrinol Metab on March 29, 2013
Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women | NCT01440803
Bisphosphonates for Prevention of Post-Denosumab Bone Loss | NCT03396315
Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study. J Clin Endocrinol Metab (2014) 0.94
PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int (2014) 0.87
Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. Cell Metab (2017) 0.85
Fractal lacunarity of trabecular bone and magnetic resonance imaging: New perspectives for osteoporotic fracture risk assessment. World J Orthop (2015) 0.80
Mechanisms of marrow adiposity and its implications for skeletal health. Metabolism (2016) 0.79
In vivo assessment of bone structure and estimated bone strength by first- and second-generation HR-pQCT. Osteoporos Int (2016) 0.78
A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int (2016) 0.77
Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis. J Clin Endocrinol Metab (2015) 0.76
Evaluation and management of the premenopausal woman with low BMD. Curr Osteoporos Rep (2013) 0.76
Premenopausal bone health: osteoporosis in premenopausal women. Clin Obstet Gynecol (2013) 0.76
Prevention and treatment of bone changes associated with exposure to glucocorticoids. Curr Osteoporos Rep (2013) 0.76
Teriparatide for osteoporosis: importance of the full course. Osteoporos Int (2016) 0.75
Current perspectives on the etiology and manifestation of the "silent" component of the Female Athlete Triad. Int J Womens Health (2014) 0.75
Premenopausal Osteoporosis. Endocrinol Metab Clin North Am (2016) 0.75
Bone microarchitecture in Rett syndrome and treatment with teriparatide: a case report. Osteoporos Int (2016) 0.75
Bone Mineral Density Response from Teriparatide in Patients with Osteoporosis. HSS J (2017) 0.75
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60
Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res (1999) 6.39
Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (2013) 5.93
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Mechanisms of anabolic therapies for osteoporosis. N Engl J Med (2007) 3.33
Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab (1997) 3.00
A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int (1996) 2.98
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res (2001) 2.65
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res (2009) 2.48
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res (2003) 2.38
Idiopathic osteoporosis--is the osteoblast to blame? J Clin Endocrinol Metab (1997) 2.25
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab (2000) 2.14
Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res (2000) 1.91
Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest (1998) 1.75
Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab (2006) 1.60
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res (2005) 1.57
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Osteoporos Int (2008) 1.35
Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res (2001) 1.33
Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA (1998) 1.30
The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res (2012) 1.28
Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone. J Clin Invest (1995) 1.27
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab (2005) 1.14
Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res (2007) 1.12
Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab (2011) 1.11
Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol (2006) 1.10
Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol (2011) 1.07
Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res (2012) 1.07
Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res (2000) 1.05
Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. J Bone Miner Res (1995) 1.04
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int (2010) 1.04
Premenopausal women with idiopathic low-trauma fractures and/or low bone mineral density. Osteoporos Int (2011) 1.03
The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res (2000) 1.02
Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact. J Bone Miner Res (2010) 0.98
hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int (1991) 0.98
Increased marrow adiposity in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab (2012) 0.96
Decreased DNA synthesis by cultured osteoblastic cells in eugonadal osteoporotic men with defective bone formation. J Clin Invest (1991) 0.94
Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int (2009) 0.94
Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab (1999) 0.91
Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. J Bone Miner Res (2010) 0.91
Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men. J Clin Endocrinol Metab (1997) 0.89
Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone (2006) 0.89
Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center. J Womens Health (Larchmt) (2009) 0.88
Bone histomorphometry in male idiopathic osteoporosis. Calcif Tissue Int (2009) 0.86
Treatment of premenopausal women with low bone mineral density. Curr Osteoporos Rep (2008) 0.84
Osteoblast dysfunction in male idiopathic osteoporosis. Calcif Tissue Int (2006) 0.84
Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res (2009) 0.83
Role of IGF-I on PTH effects on bone. J Endocrinol Invest (2010) 0.82
Vertebral fractures are associated with increased cortical porosity in iliac crest bone biopsy of men with idiopathic osteoporosis. Bone (2008) 0.82
PTH circadian rhythm and PTH target-organ sensitivity is altered in patients with adult growth hormone deficiency with low BMD. J Bone Miner Res (2007) 0.80
Bone histomorphometry in 22 male patients with normocalciuric idiopathic osteoporosis. Bone (2005) 0.80
Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone. Endocrinology (1990) 0.79
Variability in the measured response of bone to teriparatide. Osteoporos Int (2010) 0.79
Should bisphosphonates be used in premenopausal women? Maturitas (2010) 0.77
Osteoporosis of unknown cause in younger people: idiopathic osteoporosis. J Bone Joint Surg Br (1958) 0.76
Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res (2010) 9.95
Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr (2007) 9.61
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet (2001) 6.56
Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (2013) 5.93
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76
The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab (2007) 4.00
Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol (2003) 3.71
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med (2004) 3.44
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity. Hum Mol Genet (2008) 3.24
Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem (2006) 3.10
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol (2009) 2.97
Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts outcomes. Kidney Int (2011) 2.94
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Relationship of obesity with osteoporosis. J Clin Endocrinol Metab (2007) 2.71
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69
Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet (2008) 2.65
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res (2015) 2.49
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int (2008) 2.37
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab (2010) 2.29
Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg (2008) 2.25
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol (2006) 2.18
Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab (2011) 2.16
Quantitative evaluation of mechanical properties in tissue-engineered auricular cartilage. Tissue Eng Part B Rev (2013) 2.14
Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groups. Am J Hum Genet (2009) 2.14
The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab (2008) 2.12
Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res (2007) 2.11
Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2005) 2.05
Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab (2010) 2.02
High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone. J Bone Miner Res (2010) 2.01
Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke (2007) 1.96
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res (2010) 1.95
Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci (2008) 1.92
A genomewide linkage scan for quantitative-trait loci for obesity phenotypes. Am J Hum Genet (2002) 1.91
Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol (2006) 1.91
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab (2013) 1.88
Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr (2010) 1.87
Differences in bone microarchitecture between postmenopausal Chinese-American and white women. J Bone Miner Res (2011) 1.86
Mendel: the Swiss army knife of genetic analysis programs. Bioinformatics (2013) 1.85
Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab (2011) 1.81
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res (2005) 1.78
Abnormal microarchitecture and reduced stiffness at the radius and tibia in postmenopausal women with fractures. J Bone Miner Res (2010) 1.78
PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure. J Cell Biol (2003) 1.78
MRI of the basement membrane using charged nanoparticles as contrast agents. Magn Reson Med (2008) 1.77
Chronic kidney disease and bone fracture: a growing concern. Kidney Int (2008) 1.76
Application of high-resolution skeletal imaging to measurements of volumetric BMD and skeletal microarchitecture in Chinese-American and white women: explanation of a paradox. J Bone Miner Res (2009) 1.76
Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J Bone Miner Res (2011) 1.76
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res (2007) 1.75
Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res (2013) 1.74
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74
Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med (2011) 1.74
Bone structure at the distal radius during adolescent growth. J Bone Miner Res (2009) 1.74
CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production. Proc Natl Acad Sci U S A (2005) 1.73
Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. Am J Physiol Renal Physiol (2007) 1.72
Mutation patterns at dinucleotide microsatellite loci in humans. Am J Hum Genet (2002) 1.71
Bone fragility and collagen cross-links. J Bone Miner Res (2004) 1.68
Quantity and quality of trabecular bone in the femur are enhanced by a strongly anabolic, noninvasive mechanical intervention. J Bone Miner Res (2002) 1.68
The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci (2007) 1.66
Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol (2006) 1.64
Dentin sialoprotein and dentin phosphoprotein have distinct roles in dentin mineralization. Matrix Biol (2009) 1.64
Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell (2012) 1.62
Trabecular bone histomorphometry in humans with Type 1 Diabetes Mellitus. Bone (2011) 1.61
Bone microarchitecture and stiffness in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab (2009) 1.61